IASO-782 for Systemic Lupus Erythematosus

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1, randomized, double-blind, placebo-controlled study evaluates multiple doses of IASO-782 in adults with SLE to determine safety and initial dosing ranges. Participants receive IASO-782 or placebo at 4, 6, or 10 mg/kg, with careful monitoring for adverse events and lab changes. The study uses a parallel-group escalation to identify a safe dose range for further testing. Enrollment targets adults with a confirmed SLE diagnosis who are on standard therapies and meet health criteria, with exclusions for recent cardiac disease or certain cancers. The lead sponsor is Shanghai IASO Biotechnology Co., Ltd, with participating centers in Hangzhou and nearby institutions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged 18 to 75 years;
2. Clinically confirmed diagnosis of SLE before screening;
3. Currently receiving standard treatment regimens, including any single drug or combination of drugs;
4. Organ function or laboratory test is basically normal;
5. Subjects with potential fertility and their partners must use effective contraceptive measures for at least 2 weeks before the first dose of the study drug, throughout the study period, and for 6 months after the end of the study (or early termination of the study);
6. Females with potential fertility must have a negative pregnancy test during the Screening Phase;
7. Voluntarily participate in the study and sign the informed consent form.

Exclusion Criteria:

1. History of other primary malignant neoplasm within 5 years of screening;
2. A history of cardiac disease within the recent 3 months, including New York Heart Association (NYHA) Class III/IV congestive heart failure and cardiac arrhythmias requiring drug treatment;
3. Subjects with poorly controlled hypertension despite drug treatment;
4. A history of hypersensitivity to any component of the study drug or its excipients confirmed before screening;
5. Presence of active infection requiring intravenous drug treatment within 30 days before screening;
6. Pregnant or lactating females;
7. Participation in any other clinical trial within 28 days before randomization or within 5 half-lives of the study drug in the other trial (whichever is longer);
8. Previous treatment drugs have not been adequately washed out;
9. A previous history of any arterial or venous thrombosis (stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis or pulmonary embolism), or clinical symptoms and medical history suggesting thrombophilia; or any of the following: cardiac arrhythmias known to increase the risk of thrombotic events (e.g., atrial fibrillation), or a corrected QT interval (QTc) \>450 msec in the subject; or a history of other coagulation abnormalities;
10. Confirmed diagnosis of severe lupus nephritis within 8 weeks before screening (defined as urine protein \>6 g/24 hours or serum creatinine \>2.5 mg/dL or 221 μmol/L), or requiring treatment with study-prohibited drugs, or having active nephritis requiring prednisone ≥100 mg/day or equivalent glucocorticoid for ≥14 days; active severe or unstable neuropsychiatric SLE, including but not limited to poorly controlled seizures, psychosis or acute confusional state, cerebrovascular accident, demyelinating syndrome, cranial nerve palsy, or evidence of active central nervous system vasculitis within 12 weeks before the screening visit;
11. Hepatitis B virus (HBV) infection during the Screening Phase (if HBsAg is positive, or HBsAg is negative but anti-HBc is positive, HBV-DNA testing is required, and the subject will be excluded if viral replication is indicated); positive anti-hepatitis C virus (HCV) antibody with positive peripheral blood HCV RNA; positive human immunodeficiency virus (HIV) antibody; positive specific treponema pallidum antibody with positive rapid plasma reagin test;
12. Tuberculosis (TB) infection: TB testing will be appropriately performed during screening according to local clinical practice. Subjects with active tuberculosis will be excluded, except for those with latent TB who are judged by the investigator to be eligible for the study;
13. A history of substance abuse or mental disorders;
14. Any other medical history or condition judged by the investigator to be unsuitable for study participation.

Where it's running

• Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine
  Hangzhou, Zhejiang, China Recruiting
• The First Affiliated Hospital, Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting
• Huzhou Central Hospital
  Huzhou, Zhejiang, China Recruiting
• The First Hospital of Jiaxing
  Jiaxing, Zhejiang, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SLE Registry in Pakistan to understand how lupus presents and progresses

  This project is building a Pakistan lupus registry to see how SLE shows up and changes over time in adults, starting at Fauji Foundation Hospital Rawalpindi.

  Recruiting Foundation University Islamabad · Rawalpindi, Punjab Province · NCT07902622

• FT819 in Lupus Nephritis: a targeted cell therapy trial for moderate-to-severe LN

  This trial tests whether FT819, a donor-derived CAR T cell therapy, can help people with difficult-to-treat lupus nephritis who have not responded to other medicines.

  Recruiting at 12 sites Phase 2 Fate Therapeutics · Beverly Hills, California and 11 other locations · NCT07570862

• Dual-target CAR T therapy (CD19 and BCMA) for relapsed or treatment-resistant autoimmune diseases

  This will try a single infusion of off-the-shelf (allogeneic) CAR T-cells that target CD19 and BCMA in adults whose autoimmune disease has relapsed or not responded to other treatments.

  Recruiting Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07315087

• Umbilical cord blood CAR-T therapy for refractory systemic lupus erythematosus

  This will test an off-the-shelf umbilical cord blood–derived CAR‑T cell therapy targeting CD19 and BCMA to see if it helps adults with treatment‑resistant SLE.

  Recruiting Early Phase 1 Chengdu Ucello Biotechnology Co., Ltd. · Yancheng, Jiangsu and 1 other locations · NCT07274059

• CC312 for relapsed or treatment‑resistant lupus, inflammatory myopathies, and systemic sclerosis

  This early-phase test will try CC312 to see if it is safe and may help adults aged 18–65 with relapsed or treatment‑resistant systemic lupus erythematosus, idiopathic inflammatory myopathies, or systemic sclerosis.

  Recruiting Early Phase 1 CytoCares Inc · Deyang, Sichuan · NCT07193810

• CC312 for adults with moderate to severe lupus

  This Phase 1 trial will test whether CC312 is safe and shows early benefit in adults with moderate to severe lupus.

  Recruiting Phase 1 CytoCares Inc · Chengdu, Sichuan · NCT07177911

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.